Cipher receives Patent Notice of Allowance for CIP-ISOTRETINOIN
Cipher Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-ISOTRETINOIN, the Company's novel formulation of the acne medication isotretinoin. The required issue and publication fees will now be paid so that the patent can be issued.
The patent includes claims related to the reduced food effect of CIP-ISOTRETIOIN relative to currently marketed formulations.
"Having the U.S. patent allowed represents an important milestone on our path to commercialization for CIP-ISOTRETINOIN," said Larry Andrews, President & CEO of Cipher. "It also reinforces that the product is truly differentiated from currently marketed formulations."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Scientists map epigenetic changes during blood cell differentiation - Potential application for stem cell therapies
Sartorius closes acquisition of TAP Biosystems Group plc
Purple_acid_phosphatases

Turning straw into gold?
BRAIN-led industrial NatLifE 2020 innovation alliance started after receipt of approval - First Innovation Alliance to receive approval letter

New approach explains how protein complexes regulate cancer genes - New starting point for improved cancer therapies
Digestive_disease
Cipher receives Patent Notice of Allowance for CIP-ISOTRETINOIN
Asystole
Tyrosine_kinase_2
